Comparative evaluation of feature reduction methods for drug response prediction
Personalized medicine aims to tailor medical treatments to individual patients, and predicting drug responses from molecular profiles using machine learning is crucial for this goal. However, the high dimensionality of the molecular profiles compared to the limited number of samples presents significant challenges. Knowledge-based feature selection methods are particularly suitable for drug response prediction, as they leverage biological insights to reduce dimensionality and improve model interpretability. This study presents the first comparative evaluation of nine different knowledge-based and data-driven feature reduction methods on cell line and tumor data. Our analysis employs six distinct machine learning models, with a total of more than 6,000 runs to ensure a robust evaluation. Our findings indicate that transcription factor activities outperform other methods in predicting drug responses, effectively distinguishing between sensitive and resistant tumors for seven of the 20 drugs evaluated.
Authors
- Farzaneh Firoozbakht (ORCID: https://orcid.org/0000-0002-4737-3133)
- Behnam Yousefi (ORCID: https://orcid.org/0000-0003-0995-2000)
- Benno Schwikowski (ORCID: https://orcid.org/0000-0001-5127-5619)
- Olga Tsoy (ORCID: https://orcid.org/0000-0002-7592-2080)
- Jan Baumbach (ORCID: https://orcid.org/0000-0002-0282-0462)
Institutions
- Institut Pasteur (FR)
- Universität Hamburg (DE)
- University of Southern Denmark (DK)
- Université Sorbonne Nouvelle (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- University Medical Center Hamburg-Eppendorf (DE)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1038/s41598-024-81866-1
- Citations
- 2
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- European Commission
- Agence Nationale de la Recherche
- Bundesministerium für Bildung und Forschung
- Horizon 2020 Framework Programme
- HORIZON EUROPE Marie Sklodowska-Curie Actions